Navigation Links
FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
Date:4/3/2012

SAN DIEGO and DALLAS, April 3, 2012 /PRNewswire-iReach/ -- FirstMark today announced the appointment of Jay Houtman as the company's new Regional Sales Manager for the Southeast region of the United States. Houtman will be based out of Dallas Texas. His primary role will be to drive growth and awareness for FirstMark's new cardiovascular test PREvent. PREvent is a simple blood test that distinguishes the top 5 percent of suspected or confirmed coronary artery disease patients that are at a 5.5 times greater risk of a near term (2-3 years) heart attack.

"Heart disease is the number one cause of death in the U.S. There is a pervasive need for PREvent to identify patients at risk in the Southeast region of the country. I am confident that Jay will help infuse FirstMark with strong, disciplined professional sales management to support our corporate growth initiatives for PREvent, while building and fostering strong relationships with physicians in this territory," said Thomas Silberg, President and CEO of GenWay Biotech.

Houtman brings a unique depth of experience in sales, customer service, training and technical expertise in cardiovascular and oncology, diagnostic and pharmaceutical solutions. Previous experience includes sales management positions with Bristol-Myers Squibb, Sanofi-Aventis and Gambro. He has consistently ranked with these companies as first in the nation and various regions for sales performance and customer service. Houtman received his B.S. in Health Sciences from the University of Oklahoma.

"The opportunity with FirstMark is phenomenal," said Houtman. "It isn't often that a novel test like this comes along that is so rich in data and supported by leading cardiologists. I am thrilled to have the opportunity to represent PREvent and its potential to save lives from heart attacks."

About PREvent

PREvent is the first and only multiple biomarker blood test on the market that accurately predicts the risk of near term (2-3 years) myocardial infarction or death in patients with suspected or confirmed, insignificant or significant coronary artery disease. Research has discovered that there are multiple pathways that lead to formation of vulnerable plaques. PREvent aggregates three cardiovascular biomarkers that identify these pathways, and projects the propensity for an individual to develop vulnerable plaque. PREvent provides physician's diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment, compliance and monitoring.

About FirstMark

FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit FirstMarkPREvent.com.

Media Contact:

Deborah Moore GenWay Biotech, 858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE FirstMark
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
2. ChromaDex® Announces Financial Results for the Year Ended 2011
3. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
4. Pew announces 2012 recipients of distinguished Marine Conservation Fellowship
5. PNAS announces 6 2011 Cozzarelli Prize recipients
6. ChromaDex® Announces Management Changes
7. Collaborative Health Consortium Announces eCollaboration Forum Final Agenda for HIMSS 2012
8. Medbox, Inc. Announces New Product Line for 2012
9. FASEB SRC announces conference registration open for: Virus Structure and Assembly
10. Elsevier announces publishing the Ocular Surface
11. Biophysical Society announces New and Notable Symposium speakers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... FREDERICK, Md. (PRWEB) , ... ... ... company, Molecular Biology Systems, B.V. (MBS) has announced a publication detailing the ... a one-step reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The ...
(Date:6/28/2020)... ... 2020 , ... In an upcoming episode scheduled for the fall of 2020, ... solutions (POCT). Check local listings for more info. , Today, the majority of testing ... to labs throughout the country. Results are then available several days later. Now, in ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... The field ... Typically, ligand binding assays (LBA) have dominated this area. However, the use of mass ... years. , This now necessitates the question “How do you choose which approach to ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said Matt ... the market and we were pleased that the IFT jury recognized that.” reFRESH™ couples ... a natural way to extend the shelf life and improve the safety of perishable ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode ... significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . ... , Bode-CARES provides a turnkey solution that includes a comprehensive ...
Breaking Biology Technology: